iBio Management
Management criteria checks 2/4
iBio's CEO is Martin Brenner, appointed in Jan 2021, has a tenure of less than a year. total yearly compensation is $1.27M, comprised of 41.1% salary and 58.9% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $24.73K. The average tenure of the management team and the board of directors is 2.4 years and 5 years respectively.
Key information
Martin Brenner
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 41.1% |
| CEO tenure | 4yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.4yrs |
| Board average tenure | 5yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$14m |
| Jun 30 2024 | US$1m | US$522k | -US$15m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | n/a | n/a | -US$21m |
| Sep 30 2023 | n/a | n/a | -US$27m |
| Jun 30 2023 | US$1m | US$458k | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$35m |
| Dec 31 2022 | n/a | n/a | -US$35m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | US$1m | US$405k | -US$30m |
| Mar 31 2022 | n/a | n/a | -US$19m |
| Dec 31 2021 | n/a | n/a | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$21m |
| Jun 30 2021 | US$1m | US$178k | -US$23m |
Compensation vs Market: Martin's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD641.95K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Brenner (54 yo)
4yrs
Tenure
US$1,271,286
Compensation
Dr. Martin B. Brenner DVM., Ph D., is Chief Executive Officer of iBio, Inc. from June 27, 2023 and serves as its Director since June 01, 2024. Dr. Brenner was Interim CEO of iBio, Inc. from January 20, 202...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | 4yrs | US$1.27m | 0.10% $ 24.7k | |
| Chief Financial Officer | 1.9yrs | US$761.87k | 0.021% $ 5.3k | |
| Chief Legal Officer | 2.9yrs | no data | 0.020% $ 5.1k | |
| Senior VP of Business Development | less than a year | no data | no data |
2.4yrs
Average Tenure
Experienced Management: IBIO's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, Chief Scientific Officer & Director | less than a year | US$1.27m | 0.10% $ 24.7k | |
| Member of Scientific Advisory Board | 4.1yrs | US$291.75k | no data | |
| Independent Chairman | 3.4yrs | US$89.08k | 0% $ 0 | |
| Lead Independent Director | 4.3yrs | US$66.00k | 0% $ 0 | |
| Member of Scientific Advisory Board | 20.3yrs | no data | no data | |
| Member of Clinical Advisory Board | 10.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 10.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 10.5yrs | no data | no data | |
| Member of Clinical Advisory Board | 10.3yrs | no data | no data | |
| Independent Director | 5.8yrs | US$56.67k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$52.50k | 0% $ 0 | |
| Independent Director | less than a year | no data | no data |
5.0yrs
Average Tenure
55.5yo
Average Age
Experienced Board: IBIO's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 09:33 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
iBio, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Keay Nakae | Chardan Capital Markets, LLC |